CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.16
2.6%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.14
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

LENSAR Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.08
Open* 2.98
1-Year Change* 18.73%
Day's Range* 2.98 - 3.19
52 wk Range 1.80-4.80
Average Volume (10 days) 42.95K
Average Volume (3 months) 606.89K
Market Cap 43.76M
P/E Ratio -100.00K
Shares Outstanding 11.25M
Revenue 40.29M
EPS -1.23
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 14, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 3.16 0.17 5.69% 2.99 3.19 2.98
Apr 11, 2024 3.08 0.09 3.01% 2.99 3.18 2.99
Apr 10, 2024 2.99 -0.17 -5.38% 3.16 3.24 2.98
Apr 9, 2024 3.19 0.07 2.24% 3.12 3.30 3.12
Apr 8, 2024 3.18 0.12 3.92% 3.06 3.22 2.67
Apr 5, 2024 2.99 0.01 0.34% 2.98 3.16 2.83
Apr 4, 2024 3.16 -0.15 -4.53% 3.31 3.37 3.11
Apr 3, 2024 3.30 -0.01 -0.30% 3.31 3.39 3.23
Apr 2, 2024 3.30 -0.10 -2.94% 3.40 3.49 3.30
Apr 1, 2024 3.36 -0.02 -0.59% 3.38 3.45 3.24
Mar 28, 2024 3.37 -0.11 -3.16% 3.48 3.58 3.37
Mar 27, 2024 3.63 0.26 7.72% 3.37 3.72 3.37
Mar 26, 2024 3.48 0.09 2.65% 3.39 3.55 3.39
Mar 25, 2024 3.39 -0.11 -3.14% 3.50 3.51 3.03
Mar 22, 2024 3.42 -0.17 -4.74% 3.59 3.72 3.31
Mar 21, 2024 3.57 -0.30 -7.75% 3.87 4.02 3.48
Mar 20, 2024 3.94 0.44 12.57% 3.50 3.95 3.48
Mar 19, 2024 3.49 -0.99 -22.10% 4.48 4.49 3.49
Mar 18, 2024 4.05 0.19 4.92% 3.86 4.13 3.75
Mar 15, 2024 3.88 0.32 8.99% 3.56 3.95 3.56

LENSAR, Inc. Events

Time (UTC) Country Event
Tuesday, May 7, 2024

Time (UTC)

15:00

Country

US

Event

LENSAR Inc Annual Shareholders Meeting
LENSAR Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, May 13, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 LENSAR Inc Earnings Release
Q1 2024 LENSAR Inc Earnings Release

Forecast

-

Previous

-
Friday, May 24, 2024

Time (UTC)

14:00

Country

US

Event

LENSAR Inc Annual Shareholders Meeting
LENSAR Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, August 7, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 LENSAR Inc Earnings Release
Q2 2024 LENSAR Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 35.358 34.459 26.382 30.528 24.388
Revenue 35.358 34.459 26.382 30.528 24.388
Cost of Revenue, Total 15.403 16.626 12.307 17.299 13.64
Gross Profit 19.955 17.833 14.075 13.229 10.748
Total Operating Expense 55.535 54.111 44.884 43.242 33.704
Selling/General/Admin. Expenses, Total 27.17 23.887 23.768 17.147 16.143
Research & Development 11.814 12.358 7.553 7.569 2.784
Depreciation / Amortization 1.148 1.24 1.256 1.227 1.137
Operating Income -20.177 -19.652 -18.502 -12.714 -9.316
Interest Income (Expense), Net Non-Operating 0.263 0.051 -1.286 -2.001 -3.321
Other, Net 0.014 0.058 0.064
Net Income Before Taxes -19.914 -19.601 -19.774 -14.657 -12.573
Net Income After Taxes -19.914 -19.601 -19.774 -14.657 -12.593
Net Income Before Extra. Items -19.914 -19.601 -19.774 -14.657 -12.593
Net Income -19.914 -19.601 -19.774 -14.657 -12.593
Total Adjustments to Net Income 0 -1.451
Income Available to Common Excl. Extra. Items -19.914 -19.601 -19.774 -14.657 -14.044
Income Available to Common Incl. Extra. Items -19.914 -19.601 -19.774 -14.657 -14.044
Diluted Net Income -19.914 -19.601 -19.774 -14.657 -14.044
Diluted Weighted Average Shares 10.159 9.374 4.621 10.6346 10.6346
Diluted EPS Excluding Extraordinary Items -1.96023 -2.091 -4.27916 -1.37824 -1.3206
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.96023 -2.091 -4.27916 -1.37824 -1.3206
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 12.012 8.252 10.232 7.748 8.038
Revenue 12.012 8.252 10.232 7.748 8.038
Cost of Revenue, Total 5.251 3.932 3.75 3.859 3.146
Gross Profit 6.761 4.32 6.482 3.889 4.892
Total Operating Expense 14.879 12.613 12.845 11.831 14.836
Selling/General/Admin. Expenses, Total 7.854 6.755 7.204 6.119 7.569
Research & Development 1.499 1.65 1.615 1.577 3.834
Depreciation / Amortization 0.275 0.276 0.276 0.276 0.287
Operating Income -2.867 -4.361 -2.613 -4.083 -6.798
Interest Income (Expense), Net Non-Operating 0.111 0.089 0.123 0.092 0.039
Net Income Before Taxes -8.753 -4.272 -2.49 -3.991 -6.759
Net Income After Taxes -8.753 -4.272 -2.49 -3.991 -6.759
Net Income Before Extra. Items -8.753 -4.272 -2.49 -3.991 -6.759
Net Income -8.753 -4.272 -2.49 -3.991 -6.759
Income Available to Common Excl. Extra. Items -8.753 -4.272 -2.49 -3.991 -6.759
Income Available to Common Incl. Extra. Items -8.753 -4.272 -2.49 -3.991 -6.759
Diluted Net Income -8.753 -4.272 -2.49 -3.991 -6.759
Diluted Weighted Average Shares 10.82 10.716 10.369 10.225 10.073
Diluted EPS Excluding Extraordinary Items -0.80896 -0.39866 -0.24014 -0.39032 -0.671
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.80896 -0.39866 -0.24014 -0.39032 -0.671
Other, Net -5.997
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 33.716 44.813 58.385 17.183 11.747
Cash and Short Term Investments 14.674 31.637 40.599 4.615 3.344
Cash 40.599 4.615 3.344
Total Receivables, Net 6.24 4.988 2.456 3.886 3.774
Accounts Receivable - Trade, Net 6.04 4.638 2.012 3.384 3.302
Total Inventory 11.74 6.488 13.473 8.064 4.062
Prepaid Expenses 1.062 1.7 1.857 0.618 0.567
Total Assets 55.844 66.465 79.12 34.536 28.885
Property/Plant/Equipment, Total - Net 9.509 10.597 8.083 3.004 3.616
Property/Plant/Equipment, Total - Gross 20.203 19.34 15.719 9.865 8.365
Accumulated Depreciation, Total -10.694 -8.743 -7.636 -6.861 -4.749
Intangibles, Net 12.122 10.87 12.11 13.366 12.293
Note Receivable - Long Term 0.442 0.121 0.452 0.827 0.753
Other Long Term Assets, Total 0.055 0.064 0.09 0.156 0.476
Total Current Liabilities 11.421 8.714 8.467 7.829 7.66
Accounts Payable 5.422 2.694 2.481 1.577 1.412
Accrued Expenses 5.231 5.116 5.063 5.333 3.623
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.768 0.904 0.923 0.919 2.625
Total Liabilities 13.86 11.586 11.91 65.089 49.35
Total Long Term Debt 0 0 0 56.617 41.211
Long Term Debt 0 56.617 41.211
Other Liabilities, Total 2.439 2.872 3.443 0.643 0.479
Total Equity 41.984 54.879 67.21 -30.553 -20.465
Common Stock 0.111 0.11 0.109 0.096 0.096
Additional Paid-In Capital 139.381 132.363 125.094 7.536 2.967
Retained Earnings (Accumulated Deficit) -97.508 -77.594 -57.993 -38.185 -23.528
Total Liabilities & Shareholders’ Equity 55.844 66.465 79.12 34.536 28.885
Total Common Shares Outstanding 11.102 10.99 10.933 10.6346 10.6346
Cash & Equivalents 14.674 31.637
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 48.645 49.164 29.975 33.716 32.171
Cash and Short Term Investments 24.92 25.466 7.97 14.674 19.293
Cash & Equivalents 24.92 25.466 7.97 14.674 19.293
Total Receivables, Net 5 4.643 5.267 6.24 3.686
Accounts Receivable - Trade, Net 4.736 4.048 5.064 6.04 3.56
Total Inventory 17.481 18.152 15.668 11.74 7.89
Prepaid Expenses 1.244 0.903 1.07 1.062 1.302
Total Assets 70.853 71.196 51.961 55.844 54.801
Property/Plant/Equipment, Total - Net 7.438 6.764 6.768 6.879 7.371
Intangibles, Net 11.298 11.571 11.845 12.122 12.398
Note Receivable - Long Term 1.131 1.221 0.768 0.442 0
Other Long Term Assets, Total 2.341 2.476 2.605 2.685 2.861
Total Current Liabilities 11.011 10.556 9.992 11.421 9.788
Accounts Payable 3.936 4.619 4.923 5.422 3.506
Accrued Expenses 6.011 4.87 4.037 5.231 5.474
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.064 1.067 1.032 0.768 0.808
Total Liabilities 20.723 24.759 12.523 13.86 12.218
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 9.712 14.203 2.531 2.439 2.43
Total Equity 50.13 46.437 39.438 41.984 42.583
Common Stock 0.112 0.112 0.111 0.111 0.11
Additional Paid-In Capital 144.236 143.111 141.107 139.381 137.491
Retained Earnings (Accumulated Deficit) -107.965 -110.533 -101.78 -97.508 -95.018
Total Liabilities & Shareholders’ Equity 70.853 71.196 51.961 55.844 54.801
Total Common Shares Outstanding 11.246 11.199 11.103 11.102 11.023
Redeemable Preferred Stock 13.747 13.747
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -19.914 -19.601 -19.774 -14.657 -12.593
Cash From Operating Activities -14.856 -8.969 -13.791 -12.589 -1.885
Cash From Operating Activities 2.258 1.524 1.309 2.639 3.453
Amortization 1.148 1.24 1.256 1.227 1.137
Non-Cash Items 7.229 7.91 9.607 0.561 0.197
Cash Taxes Paid 0.003 0.019 0 0
Cash Interest Paid 0 0 0.478 0.473 0.272
Changes in Working Capital -5.577 -0.042 -6.189 -2.359 5.921
Cash From Investing Activities -0.115 -0.354 -0.326 -2.089 -3.892
Capital Expenditures -0.115 -0.354 -0.366 -2.089 -3.892
Cash From Financing Activities -1.992 0.361 50.001 15.949 6.955
Financing Cash Flow Items -2.4 -1.071 -0.214
Issuance (Retirement) of Stock, Net 0.408 0.361 37.601 3.795 3.669
Issuance (Retirement) of Debt, Net 0 12.4 13.225 3.5
Net Change in Cash -16.963 -8.962 35.884 1.271 1.178
Other Investing Cash Flow Items, Total 0 0.04
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.272 -19.914 -17.424 -13.433 -6.674
Cash From Operating Activities -6.696 -14.856 -10.098 -5.397 -2.607
Cash From Operating Activities 0.578 2.258 1.681 1.11 0.541
Amortization 0.276 1.148 0.872 0.596 0.309
Non-Cash Items 1.853 7.229 5.491 3.629 1.871
Cash Interest Paid 0.001 0 0 0 0
Changes in Working Capital -5.131 -5.577 -0.718 2.701 1.346
Cash From Investing Activities -0.008 -0.115 -0.058 -0.056 -0.046
Capital Expenditures -0.008 -0.115 -0.058 -0.056 -0.046
Cash From Financing Activities -1.992 -2.188 -0.988
Issuance (Retirement) of Debt, Net
Net Change in Cash -6.704 -16.963 -12.344 -6.441 -2.653
Cash Taxes Paid 0.003 0.01 0.01
Other Investing Cash Flow Items, Total
Issuance (Retirement) of Stock, Net 0.408 0.212 0.212
Financing Cash Flow Items -2.4 -2.4 -1.2

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

LENSAR, Inc. Company profile

About LENSAR Inc

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. It is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, LENSAR Inc revenues increased 31% to $34.5M. Net loss decreased 1% to $19.6M. Revenues reflect Europe segment increase of 62% to $5.8M, South Korea segment increase of 42% to $4.4M. Lower net loss reflects Stock-based Compensation in SGA decrease of 21% to $5.9M (expense), Interest expense decrease from $1.3M (expense) to $0K.

Industry: Advanced Medical Equipment & Technology (NEC)

2800 Discovery Drive
Suite 100
ORLANDO
FLORIDA 32826
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

Gold

2,344.52 Price
-1.190% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.50

XRP/USD

0.55 Price
+0.650% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,259.33 Price
+0.930% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

67,651.20 Price
+0.690% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading